

SOHO 2024

September 4-7, 2024

George R Brown Convention Center



Scientific Program

Wednesday, September 4, 2024

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
MEET-THE-PROFESSOR SESSION I			
7:00 AM	7:45 AM	MTP Session I: AML - AML Specific Subsets Session Chair: Naval Daver	Level 3, 361 BCEF
	Secondary AML - Best Therapy	Pinkal Desai, MD, MPH	Weill Cornell Medicine, New York, New York, USA
	Is Favorable Risk AML Always Favorable?	Richard Dillon, MD	Guys Hospital Trust, London, United Kingdom
	TP53 Mutated AML - Where Are We?	Naval Daver, MD	MD Anderson Cancer Center, Houston, Texas, USA
7:00 AM	7:45 AM	MTP Session II: ALL - MRD Testing in ALL: Use of NGS in MRD Session Chair: Dieter Hoelzer	Level 3, 351 BCEF
	ALL Use of NGS in MRD	Aaron C Logan, MD, PhD, Mphil	University of California, San Francisco, California, USA
	ALL Use of Flow MRD	Alberto Orfao, MD, PhD	University of Salamanca, Salamanca, Spain
	Approach to MRD in T Cell ALL	Shira N Dinner, MD	Northwestern University, Chicago, Illinois, USA
7:00 AM	7:45 AM	MTP Session III: Lymphoma 1 Session Chair: Izidore Lossos	Level 3, 370 BE
	Management Algorithm for Nodular Lymphocyte Predominant Hodgkin Lymphoma	Ryan Lynch, MD	Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
	Current Management of Waldenstrom Macroglobulinemia	Jorge J Castillo, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
	New Agents in Marginal Zone Lymphoma	Izidore Lossos, MD	University of Miami, Miami, Florida, USA
7:00 AM	7:45 AM	MTP Session IV: Lymphoma 2 Session Chair: Sonali Smith	Level 3, 370 CF
	CAR T-Cell Therapy After CAR T-Cell Therapy for DLBCL	Frederick Locke, MD	Moffitt Cancer Center, Tampa, Florida, USA
	The Promise of Immunotherapies in T-Cell Lymphoma	Stefan K Barta, MD, MS	University of Pennsylvania, Philadelphia, Pennsylvania, USA
	T-Cell Directed Therapy for Indolent B-Cell Lymphoma	Sonali M Smith, MD	The University of Chicago Medicine, Chicago, Illinois, USA
7:00 AM	7:45 AM	MTP Session V: CML Session Chair: Michael Deininger	Level 3, 360 CF
	Therapy for Advanced Phase CML	Michael Deininger, MD, PhD	Versiti Blood Research Institute, Milwaukee, Wisconsin, USA
	Is There a Role for Combination Therapy and If So, What Combinations	Massimo Breccia, MD	Sapienza University, Rome, Italy
	The Pregnant or Want-to-Be Pregnant CML Patient	Elisabetta Abruzzese, MD, PhD	S. Eugenio University Hospital, Rome, Italy

7:00 AM	7:45 AM	MTP Session VI: MPN	Level 3, 370 AD
		Session Chair: Jason Gotlib	
		Interferon Therapy for MPNs	Abdulraheem Yacoub, MD The University of Kansas Cancer Center, Kansas City, Kansas, USA
		Managing Systemic Mastocytosis	Jason R Gotlib, MD, MS Stanford University Medical Center, Stanford, California, USA
		MDS/MPN Overlap Syndromes	Eric Padron, MD Moffitt Cancer Center, Tampa, Florida, USA
7:00 AM	7:45 AM	MTP Session VII: MDS	Level 3, 351 AD
		Session Chair: Rami Komrokji	
		Progress in CHIP/CCUS	Kelly Bolton, MD, PhD Washington University School of Medicine, St. Louis, Missouri, USA
		Investigational Studies in MDS	David A Sallman, MD Moffitt Cancer Center, Tampa, Florida, USA
		Standard of Care Approaches in MDS	Rami S Komrokji, MD Moffitt Cancer Center, Tampa, Florida, USA
7:00 AM	7:45 AM	MTP Session VIII: MM	Level 3, 371 BCEF
		Session Chair: Angela Dispenzieri	
		Monoclonal Gammopathy of Renal Significance	Nelson Leung, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
		POEMS	Angela Dispenzieri, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
		Frailty in MM	Hira Mian, MD McMaster University, Hamilton, Ontario, Canada
7:00 AM	7:45 AM	MTP Session IX: CLL - Focus on Comorbidities, Which Drug for Which Patient	Level 3, 361 AD
		Session Chair: Alessandra Ferrajoli	
		BCL2i	Barbara F Eichhorst, MD University of Cologne, Cologne, Germany
		Combos	Catherine C Coombs, MD UCI Health, Orange, California, USA
		Covalent BTKi	Lydia Scarfò, MD Università Vita-Salute San Raffaele, Milan, Italy
7:00 AM	7:45 AM	MTP Session X: CT - Real World Data Immune Effector Cells	Level 3, 371 AD
		Session Chair: Surbhi Sidana	
		Real World Data for Myeloma CAR T	Surbhi Sidana, MD Stanford University Medical Center, Stanford, California, USA
		Real World Data for All CAR T	Olalekan O Oluwole, MD, MBBS Vanderbilt University Medical Center, Nashville, Tennessee, USA
		Real World Data for CAR T for Mantle Cell Lymphoma	Sairah Ahmed, MD MD Anderson Cancer Center, Houston, Texas, USA
7:45 AM	8:00 AM	BREAK	
MEET-THE-PROFESSOR SESSION II			
8:00 AM	8:45 AM	MTP Session XI: AML - Diagnostics in AML - Recent Advances	Level 3, 361 BCEF
		Session Chair: Torsten Haferlach	
		Modern Genomic Assays in AML	Keyur Patel, MD MD Anderson Cancer Center, Houston, Texas, USA
		AI In Diagnostics	Torsten Haferlach, MD, PhD MLL Munich Leukemia Laboratory, Munich, Germany
		Application of Molecular Diagnostics in Developing Countries	Peter JM Valk, PhD Erasmus University Medical Center, Rotterdam, The Netherlands
8:00 AM	8:45 AM	MTP Session XII: ALL - Elderly ALL Approaches	Level 3, 351 BCEF
		Session Chair: Kristen O'Dwyer	
		Elderly ALL: Inotuzumab as Induction	Matthias Stelljes, MD University of Münster, Münster, Germany
		Elderly ALL: Inotuzumab/Blinatumomab	Matthew Wieduwilt, MD, PhD Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
		Elderly ALL: Low-Dose Chemotherapy and Immunotherapy Combinations	Patrice Chevallier, MD, PhD Nantes University Hospital, Nantes, France

8:00 AM	8:45 AM	MTP Session XIII: Lymphoma 1 Session Chair: Judith Trotman	Level 3, 370 BE
		Genomics in Lymphoma	Michael Green, PhD MD Anderson Cancer Center, Houston, Texas, USA
		Interpreting Baseline PET Metrics and PET-Based Response in Lymphoma	Judith Trotman, BHB, MBChB, FRACP, FRCPA Concord Repatriation General Hospital, Sydney, Australia
		Role of MRD in Lymphoma, Who, What, When, and How	Reid W Merryman, MD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
8:00 AM	8:45 AM	MTP Session XIV: Lymphoma 2 Session Chair: Eliza Hawkes	Level 3, 370 CF
		Management of High Grade B-Cell Lymphoma	Adam J Olszewski, MD Brown University, Providence, Rhode Island, USA
		Does Limited Stage DLBCL Matter?	Eliza Hawkes, MBBS Hons, FRACP, DMedSc Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia
		Novel Trial Design for B-Cell Lymphoma	Jason R Westin, MD MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	8:45 AM	MTP Session XV: CML Session Chair: Delphine Rea	Level 3, 360 CF
		Stopping Therapy (TFR) in the Real World – Which Patients, When and How to Monitor	Neil Shah, MD, PhD University of California, San Francisco, California, USA
		Defining a TKI Dose – Minimal Effect or Maximal Tolerance	Charles A Schiffer, MD Wayne State University School of Medicine, Detroit, Michigan, USA
		Atypical CML –Diagnosis and Therapy	Massimo Breccia, MD Sapienza University, Rome, Italy
8:00 AM	8:45 AM	MTP Session XVI: MPN Session Chair: Lachelle Weeks	Level 3, 370 AD
		Addressing Anemia in MF	Stephen T Oh, MD, PhD Washington University School of Medicine, St. Louis, Missouri, USA
		Challenging MPN Scenarios	Anand A Patel, MD The University of Chicago Medicine, Chicago, Illinois, USA
		When Is JAK2 CHIP and When Is It a Clonal Disease?	Lachelle D Weeks, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
8:00 AM	8:45 AM	MTP Session XVII: MDS Session Chair: Rami Komrokji	Level 3, 351 AD
		Progress in CHIP/CCUS	Kelly Bolton, MD, PhD Washington University School of Medicine, St. Louis, Missouri, USA
		Investigational Studies in MDS	David A Sallman, MD Moffitt Cancer Center, Tampa, Florida, USA
		Standard of Care Approaches in MDS	Rami S Komrokji, MD Moffitt Cancer Center, Tampa, Florida, USA
8:00 AM	8:45 AM	MTP Session XVIII: MM Session Chair: Natalie Callander	Level 3, 371 BCEF
		Supportive Care With Immunotherapy	Thomas G Martin, MD University of California San Francisco, San Francisco, California, USA
		Measuring Residual Disease – MRD, Mass Fix, etc.	Ravi Vij, MD, MBA Washington University School of Medicine, St. Louis, Missouri, USA
		Maintenance Therapy – Is or Will There Be a Winner? Which Agent(s) and for How Long	Natalie S Callander, MD University of Wisconsin, Madison, Wisconsin, USA
8:00 AM	8:45 AM	MTP Session XIX: CLL Session Chair: Paolo Ghia	Level 3, 361 AD
		Should We Note Subset 2 Positive Patients as a Specific Group Within Mutated or Unmutated CLL	Thomas Chatzikonstantinou, MD Centre for Research and Technology Hellas, Thessaloniki, Greece
		MRD As a Surrogate for PFS/OS/Clinical Implications	Othman Al-Sawaf, MD University Hospital of Cologne, Cologne, Germany
		What Prognostic Models Should We Use	Stefano Molica, MD Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom

8:00 AM	8:45 AM	MTP Session XX: CT - Stem Cell Transplant	Level 3, 371 AD
		Session Chair: Sergio Giral	
		New Treatment Options for Chronic GVHD	Steven Z Pavletic, MD, PhD National Cancer Institute, Bethesda, Maryland, USA
		CHARM Study Implications for Patients and Physicians	Mohamed Sorrow, MD, MSc Fred Hutchinson Cancer Center, Seattle, Washington, USA
		Survivorship Issues for Stem Cell Transplant and CAR T	Minoo Battiwalla, MD, MS Sarah Cannon Research Foundation, Nashville, Tennessee, USA
8:45 AM	9:00 AM	BREAK	
SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA			LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Josep-Maria Ribera and Partow Kebriaei			
9:00 AM	9:10 AM	Welcome and Opening Remarks	Gullermo Garcia-Manero, MD President, Society of Hematologic Oncology
9:10 AM	9:25 AM	Pharmacodynamics in Pediatric ALL	Rachel E Rau, MD Seattle Children's Hospital, Seattle, Washington, USA
9:25 AM	9:28 AM	Q&A	
9:28 AM	9:43 AM	Success of Modified AYA Therapy in Mexico	Roberta Demichelis, MD Salvador Zubirán National Institute of Medical Sciences, Mexico City, Mexico
9:43 AM	9:46 AM	Q&A	
9:46 AM	10:01 AM	Incorporating Immunotherapy into Upfront ALL Therapy	Mark R Litzow, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
10:01 AM	10:04 AM	Q&A	
10:04 AM	10:19 AM	CAR-T Cells for T Cell	Peihua Lu, MD Lu Daopei Hospital, Beijing, China
10:19 AM	10:22 AM	Q&A	
10:22 AM	10:37 AM	Transplant in ALL, Who, and When	Partow Kebriaei, MD MD Anderson Cancer Center, Houston, Texas, USA
10:37 AM	10:40 AM	Q&A	
10:40 AM	10:55 AM	Debate: Ph + ALL Can Be Treated With - Chemotherapy Free Regimens Without Transplant	Elias Jabbour, MD MD Anderson Cancer Center, Houston, Texas, USA
10:55 AM	11:10 AM	Debate: Ph + ALL Is Best Treated With - Chemotherapy and Transplant	Josep-Maria Ribera, MD, PhD Institut Català d'Oncologia Badalona, Barcelona, Spain
11:10 AM	11:16 AM	Q&A	
11:16 AM	11:26 AM	Oral Abstract ALL	
11:26 AM	11:41 AM	BREAK	
INDEPENDENT SATELLITE SYMPOSIUM I : LUNCH			LEVEL 3, THEATER ROOM 1
11:41 AM	12:41 PM	ISS I	
INDEPENDENT SATELLITE SYMPOSIUM II : LUNCH			LEVEL 3, THEATER ROOM 2
11:41 AM	12:41 PM	ISS II	
12:41 PM	12:56 PM	BREAK	
PLENARY SESSION I			LEVEL 3, GENERAL ASSEMBLY
Session Chair: Hagop Kantarjian			
12:56 PM	1:16 PM	ALL	Ching-Hon Pui, MD St. Jude Children's Research Hospital, Memphis, Tennessee, USA
<i>Recipient of the Emil J Freireich Distinguished Pioneer Award</i>			
SESSION II: MYELODYSPLASTIC SYNDROMES			LEVEL 3, GENERAL ASSEMBLY
Session Chair: Guillermo Garcia-Manero and Rami Komrokji			
1:16 PM	1:31 PM	Molecular and Cellular Basis of MDS	Simona Colla, PhD MD Anderson Cancer Center, Houston, Texas, USA
1:31 PM	1:34 PM	Q&A	

1:34 PM	1:49 PM	Progress in Lower Risk MDS	Valeria Santini, MD	University of Florence, Florence, Italy
1:49 PM	1:52 PM	Q&A		
1:52 PM	2:07 PM	Progress in Higher Risk MDS	David Valcárcel Ferreiras, MD, PhD	Vall d'Hebron University Hospital, Barcelona, Spain
2:07 PM	2:10 PM	Q&A		
2:10 PM	2:25 PM	Transplant in MDS	Sergio Giral, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
2:25 PM	2:28 PM	Q&A		
2:28 PM	2:43 PM	An International Perspective of Progress in MDS	Pierre Fenaux, MD, PhD	Hôpital Saint Louis, Paris, France
2:43 PM	2:46 PM	Q&A		
2:46 PM	2:56 PM	Oral Abstract MDS		
2:56 PM	3:26 PM	BREAK		
SESSION III: ACUTE MYELOID LEUKEMIA			LEVEL 3, GENERAL ASSEMBLY	
Session Chairs: Farhad Ravandi and Bob Löwenberg				
3:26 PM	3:41 PM	Update on Megnin Inhibitors	Eunice Wang, MD	Roswell Park Cancer Center, Buffalo, New York, USA
3:41 PM	3:44 PM	Q&A		
3:44 PM	3:59 PM	FLT3 Mutated AML Unanswered Questions	Mark J Lewis, MD, PhD	Johns Hopkins University, Baltimore, Maryland, USA
3:59 PM	4:02 PM	Q&A		
4:02 PM	4:17 PM	MRD as a Surrogate Endpoint for AML Therapy	Christopher S Hourigan, MD, DPhil	Virginia Tech FBRI Cancer Research Center, Roanoke, Virginia, USA
4:17 PM	4:20 PM	Q&A		
4:20 PM	4:35 PM	DEBATE: Azacytidine plus Venetoclax Should Be Prescribed As Listed On the Label	Keith Pratz, MD	University of Pennsylvania, Philadelphia, Pennsylvania, USA
4:35 PM	4:50 PM	DEBATE: Dose Reductions in Azacytidine plus Venetoclax Are Not Detrimental	Stéphane De Botton, MD, PhD	Institut de Cancérologie Gustave Roussy, Villejuif, France
4:50 PM	4:56 PM	Q&A		
4:56 PM	5:11 PM	Which Patients Over 70 With AML Should Be Transplanted in the First CR	Charles Craddock, CBE, FRCP, FRCPath	University of Birmingham, Birmingham, United Kingdom
5:11 PM	5:14 PM	Q&A		
5:14 PM	5:29 PM	Immune/Cellular Therapy in AML	Marion Subklewe, MD	Ludwig-Maximilians-University of Munich, Munich, Germany
5:29 PM	5:32 PM	Q&A		
5:32 PM	5:47 PM	International Expansion of Modern AML Therapy	Eduardo M Rego, MD	University of São Paulo, São Paulo, Brazil
5:47 PM	5:50 PM	Q&A		
5:50 PM	6:00 PM	Oral Abstract AML		
6:00 PM	6:15 PM	POSTER AWARDS		
6:15 PM		ADJOURN		
POSTER SESSION AND RECEPTION (Non-Accredited)			LEVEL 3, HALL B3	
6:15 PM	7:30 PM	POSTER SESSION AND RECEPTION		
INDEPENDENT SATELLITE SYMPOSIUM III: DINNER			LEVEL 3, THEATER ROOM 1	
7:30 PM	8:30 PM	ISS III		
		TBD		

Thursday, September 5, 2024

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDUSTRY EXPERT SESSION I: BREAKFAST (Non-Accredited)			LEVEL 3, THEATER ROOM 1
6:45 AM	7:45 AM	Expert Perspectives on the Real-World Management of Patients With PV and MF	
		Prithviraj Bose, MD MD Anderson Cancer Center Houston, Texas, USA	
		Raajit Rampal, MD, PhD Memorial Sloan Kettering Cancer Center New York, New York, USA	
		Pankit Vachhani, MD UAB Comprehensive Cancer Center Birmingham, Alabama, USA	
		<i>This activity is sponsored by Incyte</i>	
BREAKFAST WITH THE EXPERT I			LEVEL 3, GENERAL ASSEMBLY
6:45 AM	7:45 AM	Management of Older Patients with AML - International Perspectives	
		Moderator: Tapan Kadia, MD MD Anderson Cancer Center, Houston, Texas, USA	
		Italy - Giovanni Martinelli, MD University Hospital in Bologna, Bologna, Italy	
		India - Vikram Mathews MBBS, MD, DM, FASc Christian Medical College, Vellore, India	
		Mexico - Nidia Zapata, MD National Cancer Institute, Mexico City, Mexico	
7:45 AM	8:00 AM	BREAK	
SESSION IV: CHRONIC MYELOID LEUKEMIA			LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Hagop Kantarjian and Jeff Lipton			
8:00 AM	8:15 AM	Choosing the Best First Line Drug – Does Efficacy Make You Think About Cost	Elias Jabbour, MD MD Anderson Cancer Center, Houston, Texas, USA
8:15 AM	8:18 AM	Q&A	
8:18 AM	8:33 AM	Is the Product Monograph Dose of TKI Really What Is Necessary	Jorge E Cortés, MD Georgia Cancer Center, Augusta, Georgia, USA
8:33 AM	8:36 AM	Q&A	
8:36 AM	8:51 AM	Looking for Mutations in CML – When and How? Does Greater Sensitivity Make a Difference or Is It Even Necessary?	Simona Soverini, PhD University of Bologna, Bologna, Italy
8:51 AM	8:54 AM	Q&A	
8:54 AM	9:09 AM	Remembering to Monitor for the Long-Term Side Effects of TKI Therapy: How and for What	Tim Brümmendorf, MD RWTH Aachen University, Aachen, Germany
9:09 AM	9:12 AM	Q&A	
9:12 AM	9:27 AM	I Forgot About Allografting for CML – When Should I Remember?	Jerald P Radich, MD Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
9:27 AM	9:30 AM	Q&A	
9:30 AM	9:40 AM	Oral Abstract CML	
9:40 AM	10:10 AM	BREAK	
SESSION V: MYELOPROLIFERATIVE NEOPLASMS			LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Laura Michaelis and John Mascarenhas			
10:10 AM	10:25 AM	Optimizing Selection of Available JAK Inhibitors in MF	Prithviraj Bose, MD MD Anderson Cancer Center, Houston, Texas, USA
10:25 AM	10:28 AM	Q&A	
10:28 AM	10:43 AM	Clarifying Goals of Therapy in ET/PV	Laura C Michaelis, MD Medical College of Wisconsin, Milwaukee, Wisconsin, USA
10:43 AM	10:46 AM	Q&A	
10:46 AM	11:01 AM	Novel Combination and Non-JAK Inhibitor Therapies on the Horizon	John O Mascarenhas, MD Mount Sinai Medical Center, New York, New York, USA
11:01 AM	11:04 AM	Q&A	
11:04 AM	11:19 AM	Who, When, and How to Transplant Patients With MF	Roni Tamari, MD Memorial Sloan Kettering Cancer Center, New York, New York, USA
11:19 AM	11:22 AM	Q&A	
11:22 AM	11:37 AM	Optimizing Outcomes of Accelerated and Blast Phase MPN	Naseema Gangat, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
11:37 AM	11:40 AM	Q&A	
11:40 AM	11:50 AM	Oral Abstract MPN	

11:50 AM	12:05 PM	BREAK		
INDUSTRY EXPERT SESSION II: LUNCH (Non-Accredited)				LEVEL 3, THEATER ROOM 1
12:05 PM	1:05 PM	Myelofibrosis and Strategies for Disease Management: Key Considerations for Patient Care		
		TBD		
		<i>This activity is sponsored by GlaxoSmithKline</i>		
INDUSTRY EXPERT SESSION III: LUNCH (Non-Accredited)				LEVEL 3, THEATER ROOM 2
12:05 PM	1:05 PM	Long-Term Clinical Data From Multiple Phase 3 Trails for CALQUENCE in the Treatment of CLL/SLL		
		Moshe Yair Levy, MD Baylor University Medical Center Dallas, Texas, USA		
		<i>This activity is sponsored by AstraZeneca</i>		
1:05 PM	1:20 PM	BREAK		
PLENARY SESSION II				LEVEL 3, GENERAL ASSEMBLY
Session Chair: Susan O'Brien				
1:20 PM	1:40 PM	CLL	John Seymour, MBBS, FRACP, PhD	Peter MacCallum Cancer Centre, Melbourne, Australia
<i>Recipient of the Michael J. Keating Outstanding Achievement Award</i>				
SESSION VI: MULTIPLE MYELOMA				LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Thomas Martin and Angela Dispenzieri				
1:40 PM	1:55 PM	Frontline Therapy – Quads for Everyone? TE/TI	Ajay K Nooka, MD, MPH, FACP	Emory University, Winship Cancer Institute, Atlanta, Georgia, USA
1:55 PM	1:58 PM	Q&A		
1:58 PM	2:13 PM	Debate: CART Will Best Be Used in Early Relapse	Krina K Patel, MD, MSc	MD Anderson Cancer Center, Houston, Texas, USA
2:13 PM	2:28 PM	Debate: CART Should Be Reserved for Late Relapse > 3 Lines	Saad Z Usmani, MD, MBA, FACP	Memorial Sloan Kettering Cancer Center, New York, New York, USA
2:28 PM	2:34 PM	Q&A		
2:34 PM	2:49 PM	Definition and Treatment of HR – NDMM and Functional HR	Suzanne Lentzsch, MD, PhD	Columbia University, New York, New York, USA
2:49 PM	2:52 PM	Q&A		
2:52 PM	3:07 PM	Treatment of Early Relapse – Non CAR T Cell	Meletios A Dimopoulos, MD	Kapodistrian University of Athens School of Medicine, Athens, Greece
3:07 PM	3:10 PM	Q&A		
3:10 PM	3:25 PM	Bispecific Engagers – Sequencing – BCMA, GPTC and Resistance	Amrita Y Krishnan, MD, FACP	City of Hope Comprehensive Cancer Center, Duarte, California, USA
3:25 PM	3:28 PM	Q&A		
3:28 PM	3:43 PM	MM Therapy in Resource Constrained Including Maintenance	Vania TM Hungria, MD, PhD	Clinica São Germano, São Paulo, Brazil
3:43 PM	3:46 PM	Q&A		
3:46 PM	3:56 PM	Oral Abstract MM		
3:56 PM	4:26 PM	BREAK		
SESSION VII: CHRONIC LYMPHOCYTIC LEUKEMIA				LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Shuo Ma and Francesc Bosch				
4:26 PM	4:41 PM	Genetic Predisposition to CLL	Susan L Slager, PhD	Mayo Clinic Rochester, Rochester, Minnesota, USA
4:41 PM	4:44 PM	Q&A		
4:44 PM	4:59 PM	Novel Approaches to Richter Syndrome	Adam S Kittai, MD	Mount Sinai, Tisch Cancer Institute, New York, New York, USA
4:59 PM	5:02 PM	Q&A		
5:02 PM	5:17 PM	Can Therapy With BTKi Be Discontinued: YES	Inhye Ahn, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
5:17 PM	5:32 PM	Can Therapy With BTKi Be Discontinued: NO	Kerry A Rogers, MD	Ohio State University, Columbus, Ohio, USA
5:32 PM	5:38 PM	Q&A		

5:38 PM	5:53 PM	Is Continuous Therapy the Best Option for High-Risk Patients	William Wierda, MD, PhD	MD Anderson Cancer Center, Houston, Texas, USA
5:53 PM	5:56 PM	Q&A		
5:56 PM	6:11 PM	Patients With CLL in the Ukraine	Iryna Kriachok, PhD	National Cancer Institute, Kyiv, Ukraine
6:11 PM	6:14 PM	Q&A		
6:14 PM	6:24 PM	Oral Abstract CLL		
6:24 PM		ADJOURN		
6:24 PM	6:34 PM	BREAK		
INDEPENDENT SATELLITE SYMPOSIUM IV: DINNER				LEVEL 3, THEATER ROOM 1
6:34 PM	7:34 PM	ISS IV		
INDEPENDENT SATELLITE SYMPOSIUM V: DINNER				LEVEL 3, THEATER ROOM 2
6:34 PM	7:34 PM	An FDA Approved Treatment Option for Anemia in LR-MDS		
		Solly Chedid, MD Singing River Cancer Center Gulf Port, Mississippi, USA		
		This activity is sponsored by Bristol Myers Squibb		
7:34 PM	7:39 PM	BREAK		
INDEPENDENT SATELLITE SYMPOSIUM VI: DESSERT				LEVEL 3, THEATER ROOM 1
7:39 PM	8:39 PM	ISS VI		
		TBD		
INDEPENDENT SATELLITE SYMPOSIUM VII: DESSERT				LEVEL 3, THEATER ROOM 2
7:39 PM	8:39 PM	ISS VII		
		TBD		

Friday, September 6, 2024

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM VIII: BREAKFAST (Non-Accredited)			
6:45 AM	7:45 AM	ISS VIII	LEVEL 3, THEATER ROOM 2
		TBD	
BREAKFAST WITH THE EXPERT II			
6:45 AM	7:45 AM	CLL	LEVEL 3, GENERAL ASSEMBLY
		Thomas Kipps, MD, PhD	UC San Diego Moores Cancer Center, La Jolla, California, USA
7:45 AM	8:00 AM	BREAK	
SESSION VIII: T-CELL LYMPHOMA			
Session Chairs: Neha Mehta-Shah and Lauren Pinter-Brown			
8:00 AM	8:15 AM	A Clinically Relevant Overview of the Current PTCL Classification	LEVEL 3, GENERAL ASSEMBLY
		Ahmet Dogan, MD, PhD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
8:15 AM	8:18 AM	Q&A	
8:18 AM	8:33 AM	Optimizing Frontline Treatment for PTCL	
		Neha Mehta-Shah, MD, MSCI	Washington University School of Medicine, St. Louis, Missouri, USA
8:33 AM	8:36 AM	Q&A	
8:36 AM	8:51 AM	Emerging Novel Therapies for T-Cell Lymphoma	
		Owen A O'Connor, MD, PhD	Columbia University Medical Center, New York, New York, USA
8:51 AM	8:54 AM	Q&A	
8:54 AM	9:09 AM	Practical Approach to Management of CTCL	
		Lauren C Pinter-Brown, MD	UCI Health, Orange, California, USA
9:09 AM	9:12 AM	Q&A	
9:12 AM	9:27 AM	Diagnosis and Treatment of PTCL in South America	
		Carlos Chiattonne, MD, PhD	Santa Casa Medicine School, São Paulo, Brazil
9:27 AM	9:30 AM	Q&A	
9:30 AM	9:40 AM	Oral Abstract TCL	

9:40 AM	10:10 AM	BREAK		
SESSION IX: INDOLENT B-CELL LYMPHOMA				LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Brian Hill and Tara Graff				
10:10 AM	10:25 AM	Approach to Untreated Follicular Lymphoma, Where Are We Now and Future Directions	Brian T Hill, MD, PhD	Cleveland Clinic, Cleveland, Ohio, USA
10:25 AM	10:28 AM	Q&A		
10:28 AM	10:43 AM	How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma?	Christopher R Flowers, MD, MS	MD Anderson Cancer Center, Houston, Texas, USA
10:43 AM	10:46 AM	Q&A		
10:46 AM	11:01 AM	How to Implement the Administration of Bispecifics Into Community Oncology Practice	Tara Graff, DO, MS	Mission Cancer and Blood, Des Moines, Iowa, USA
11:01 AM	11:04 AM	Q&A		
11:04 AM	11:19 AM	Accessing Novel Therapies for Indolent Lymphoma in South America	Phillip Scheinberg, MD, PhD	Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil
11:19 AM	11:22 AM	Q&A		
11:22 AM	11:32 AM	Oral Abstract IBCL		
11:32 AM	11:47 AM	BREAK		
INDEPENDENT SATELLITE SYMPOSIUM IX: LUNCH				LEVEL 3, THEATER ROOM 1
11:47 AM	12:47 PM	ISS IX		
INDEPENDENT SATELLITE SYMPOSIUM X: LUNCH				LEVEL 3, THEATER ROOM 2
11:47 AM	12:47 PM	ISS X		
12:47 PM	1:02 PM	BREAK		
PLENARY SESSION III				LEVEL 3, GENERAL ASSEMBLY
Session Chair: Guillermo Garcia-Manero				
1:02 PM	1:22 PM	Myelodysplastic Neoplasms	Benjamin L Ebert, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
SESSION X: AGGRESSIVE B-CELL LYMPHOMA				LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Grzegorz Nowakowski and Astrid Pavlovsky				
1:22 PM	1:37 PM	Frontline DLBCL, Current Approaches and Updates on Ongoing Trials	Grzegorz S Nowakowski, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
1:37 PM	1:40 PM	Q&A		
1:40 PM	1:55 PM	Sequencing Therapies in Relapsed/Refractory Large B-Cell Lymphoma to Optimize the Chance of Cure	Gilles A Salles, MD, PhD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
1:55 PM	1:58 PM	Q&A		
1:58 PM	2:13 PM	Bispecific Antibodies in Aggressive B-Cell Lymphoma, Where Do They Fit in?	Michael Dickinson, MBBS, D Med Sc, FRACP, FRCPA	Peter MacCallum Cancer Center, Melbourne, Australia
2:13 PM	2:16 PM	Q&A		
2:16 PM	2:31 PM	What Is Dark Zone Lymphoma and Is It Clinically Relevant?	David Scott, MBChB, PhD	University of British Columbia, Vancouver, British Columbia, Canada
2:31 PM	2:34 PM	Q&A		
2:34 PM	2:49 PM	Managing Burkitt Lymphoma	Jennifer Crombie, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
2:49 PM	2:52 PM	Q&A		
2:52 PM	3:07 PM	Accessing Novel Therapies for Aggressive Lymphoma	Astrid Pavlovsky, MD	Pavlovsky Center for Hematology, Buenos Aires, Argentina
3:07 PM	3:10 PM	Q&A		
3:10 PM	3:20 PM	Oral Abstract ABCL		
3:20 PM	3:50 PM	BREAK		
SESSION XI: MANTLE CELL LYMPHOMA				LEVEL 3, GENERAL ASSEMBLY
Session Chairs: Nina Wagner-Johnston and Krish Patel				
3:50 PM	4:05 PM	What Is the Role of BTKi in the Frontline Treatment of Mantle Cell Lymphoma?	Nina D Wagner-Johnston, MD	Johns Hopkins Hospital, Baltimore, Maryland, USA
4:05 PM	4:08 PM	Q&A		

4:08 PM	4:23 PM	Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma	Craig Portell, MD	University of Virginia, Charlottesville, Virginia, USA
4:23 PM	4:26 PM	Q&A		
4:26 PM	4:41 PM	Novel Investigational Agents for the Treatment of MCL	Krish Patel, MD	Providence Swedish Cancer Institute, Seattle, Washington, USA
4:41 PM	4:44 PM	Q&A		
4:44 PM	4:59 PM	Accessing BTKi's and Other Novel Therapies for Mantle Cell Lymphoma	Guilherme F Perini, MD	Hospital Israelita Albert Einstein, Sao Paulo, Brazil
4:59 PM	5:02 PM	Q&A		
5:02 PM	5:12 PM	Oral Abstract MCL		

SESSION XII: HODGKIN LYMPHOMA **LEVEL 3, GENERAL ASSEMBLY**

Session Chair: **Ranjana Advani**

5:12 PM	5:27 PM	Advanced Stage Hodgkin Lymphoma, the End of ABVD and BEACOPP?	Stephen M Ansell, MD, PhD	Mayo Clinic Rochester, Rochester, Minnesota, USA
5:27 PM	5:30 PM	Q&A		
5:30 PM	5:45 PM	The Impact of New Frontline Regimens on the Treatment of Relapsed/Refractory Hodgkin Lymphoma	Ranjana H Advani, MD	Stanford University, Stanford, California, USA
5:45 PM	5:48 PM	Q&A		
5:48 PM	5:58 PM	Oral Abstract HL		

5:58 PM **ADJOURN**

5:58 PM 6:08 PM **BREAK**

INDUSTRY EXPERT SESSION IV: DINNER (Non-Accredited) **LEVEL 3, THEATER ROOM 1**

6:08 PM	7:08 PM	TBA		
		TBA		
		<i>This activity is sponsored by Genmab</i>		

INDUSTRY EXPERT SESSION V: DINNER (Non-Accredited) **LEVEL 3, THEATER ROOM 2**

6:08 PM	7:08 PM	IES V		
		TBD		
		<i>This activity is sponsored by Bristol Myers Squibb</i>		

7:08 PM 7:13 PM **BREAK**

INDUSTRY EXPERT SESSION VI : DESSERT (Non-Accredited) **LEVEL 3, THEATER ROOM 1**

7:13 PM	8:13 PM	Addressing Patients Who Have Myelofibrosis With Anemia – An Interactive Discussion of Ojjaara (Mometotinib)		
		TBD		
		<i>This activity is sponsored by GlaxoSmithKline</i>		

INDUSTRY EXPERT SESSION VII: DESSERT (Non-Accredited) **LEVEL 3, THEATER ROOM 2**

7:13 PM	8:13 PM	Treatment Option for R/R CLL or SLL		
		Moshe Yair Levy, MD Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas, Texas, USA		
		<i>This activity is sponsored by Bristol Myers Squibb</i>		

Saturday, September 7, 2024

TIME **TOPIC/SESSION** **SPEAKER** **AFFILIATION/ROOM**

INDEPENDENT SATELLITE SYMPOSIUM XI: BREAKFAST **LEVEL 3, THEATER ROOM 1**

6:45 AM	7:45 AM	ISS XI		
---------	---------	---------------	--	--

BREAKFAST WITH THE EXPERT III

LEVEL 3, GENERAL ASSEMBLY

6:45 AM 7:45 AM A Total Approach to MDS Guillermo Garcia-Manero, MD MD Anderson Cancer Center, Houston, Texas, USA

7:45 AM 8:00 AM **BREAK**

SESSION XIII: CELLULAR THERAPY

LEVEL 3, GENERAL ASSEMBLY

Session Chairs: Issa Khouri and Adetola Kassim

8:00 AM 8:15 AM Gene Therapy Should Be the Cell Therapy of Choice for Sickle Cell Disease Jaap-Jan Boelens, MD, PhD Memorial Sloan Kettering Cancer Center, New York, New York, USA

8:15 AM 8:18 AM **Q&A**

8:18 AM 8:33 AM Haploidentical Transplant Should Be the Cell Therapy Choice for Sickle Cell Disease Adetola Kassim, MD, MS Vanderbilt University Medical Center, Nashville, Tennessee, USA

8:33 AM 8:36 AM **Q&A**

8:36 AM 8:51 AM CD19 CAR T Therapy Should Be the Referred Therapy for Richter's Transformation Nirav N Shah, MD Medical College of Wisconsin, Milwaukee, Wisconsin, USA

8:51 AM 8:54 AM **Q&A**

8:54 AM 9:09 AM ALLO HCT Should Be the Referred Therapy for Richter's Transformation Issa F Khouri, MD MD Anderson Cancer Center, Houston, Texas, USA

9:09 AM 9:12 AM **Q&A**

9:12 AM 9:22 AM **Oral Abstract CT**

9:22 AM 9:52 AM **BREAK**

SESSION XIV: NEXT QUESTIONS

LEVEL 3, GENERAL ASSEMBLY

Session Chairs: Guillermo Garcia-Manero and Phillip Scheinberg

9:52 AM 10:02 AM Next Questions: Acute Lymphoblastic Leukemia Bijal D Shah, MD Moffitt Cancer Center, Tampa, Florida, USA

10:02 AM 10:12 AM Next Questions: Acute Myeloid Leukemia Farhad Ravandi, MD MD Anderson Cancer Center, Houston, Texas, USA

10:12 AM 10:22 AM Next Questions: Cellular Therapy Damian Green, MD Sylvester Comprehensive Cancer Center, Miami, Florida, USA

10:22 AM 10:32 AM Next Questions: Chronic Lymphocytic Leukemia Thomas Kipps, MD, PhD UC San Diego Moores Cancer Center, La Jolla, California, USA

10:32 AM 10:42 AM Next Questions: Chronic Myeloid Leukemia Timothy P Hughes, MD, MBBS South Australian Health and Medical Research Institute, Adelaide, Australia

10:42 AM 10:52 AM Next Questions: Aggressive B-Cell Lymphoma Mark J Roschewski, MD NCI Center for Cancer Research, Bethesda, Maryland, USA

10:52 AM 11:02 AM Next Questions: Indolent B-Cell Lymphoma Laurie H Sehn, MD, MPH BC Cancer Agency, Vancouver, Canada

11:02 AM 11:12 AM Next Questions: T-Cell Lymphoma Barbara Pro, MD Columbia University, New York, New York, USA

11:12 AM 11:22 AM Next Questions: Mantle Cell Lymphoma Michael Wang, MD MD Anderson Cancer Center, Houston, Texas, USA

11:22 AM 11:32 AM Next Questions: Hodgkin Lymphoma Alison J Moskowitz, MD Memorial Sloan-Kettering, New York, New York, USA

11:32 AM 11:42 AM Next Questions: Multiple Myeloma Noopur Raje, MD Massachusetts General Hospital, Boston, Massachusetts, USA

11:42 AM 11:52 AM Next Questions: Myelodysplastic Syndromes Guillermo Garcia-Manero, MD MD Anderson Cancer Center, Houston, Texas, USA

11:52 AM 12:02 PM Next Questions: Myeloproliferative Neoplasms Jason R Gotlib, MD, MS Stanford University Medical Center, Stanford, California, USA

11:52 AM 12:07 PM **Closing Remarks | Drawing** President of SOHO

ON-DEMAND ONLY CONTENT

ON-DEMAND INDEPENDENT EXPERT SESSION I

An Evidence-Based Approach to Managing Asparaginase Treatment in Pediatric and Younger Adolescent All Patients

TBD

This activity is sponsored by Servier Pharmaceuticals

SOHO ANNUAL MEETING 2024

September 4-7, 2024
George R Brown Convention Center



Program-at-a-Glance

	Wednesday Sep 04, 2024	Thursday Sep 05, 2024	Friday Sep 06, 2024	Saturday Sep 07, 2024
6:45 AM				
7:00 AM	MTP SESSION I	EXPERT BREAKFAST I	EXPERT BREAKFAST II	EXPERT BREAKFAST III
7:15 AM		IES I/ BREAKFAST	ISS VIII/ BREAKFAST	ISS XI/ BREAKFAST
7:30 AM				
7:45 AM	BREAK	BREAK	BREAK	BREAK
8:00 AM	MTP SESSION II	CML	TCL	CT
8:15 AM				
8:30 AM				
8:45 AM	BREAK			
9:00 AM	WELCOME/INTRODUCTION			
9:15 AM	ALL			
9:30 AM				
9:45 AM				
10:00 AM				
10:15 AM				
10:30 AM				
10:45 AM		MPN	IBCL	NEXT QUESTIONS
11:00 AM				
11:15 AM				
11:30 AM	BREAK			
11:45 AM				
12:00 PM	ISS I/LUNCH		ISS IX/LUNCH	
12:15 PM	ISS II/LUNCH		ISS X/LUNCH	
12:30 PM		IES II/LUNCH	IES III/LUNCH	CLOSING REMARKS/DRAWING
12:45 PM	BREAK			
1:00 PM	PLENARY I		PLENARY III	
1:15 PM				
1:30 PM	MDS		ABCL	
1:45 PM				
2:00 PM				
2:15 PM			MM	
2:30 PM				
2:45 PM				
3:00 PM	BREAK			
3:15 PM	AML			
3:30 PM				
3:45 PM				
4:00 PM				MCL
4:15 PM				
4:30 PM				
4:45 PM				
5:00 PM		CLL		
5:15 PM				
5:30 PM			HL	
5:45 PM				
6:00 PM	POSTER AWARDS			
6:15 PM				
6:30 PM	POSTER SESSION & RECEPTION			
6:45 PM			IES IV/DINNER	IES V/DINNER
7:00 PM				
7:15 PM				
7:30 PM				
7:45 PM	ISS III/DINNER			
8:00 PM			IES VI/DESSERT	IES VII/DESSERT
8:15 PM		ISS VI/DESSERT	ISS VII/DESSERT	
8:30 PM				
8:45 PM				

- Legend**
- ABCL: aggressive B-cell lymphoma
 - MDS: myelodysplastic neoplasms
 - ALL: acute lymphoblastic leukemia
 - AML: acute myeloid leukemia
 - CLL: chronic lymphocytic leukemia
 - CML: chronic myeloid leukemia
 - CT: cellular therapy
 - HL: Hodgkin lymphoma
 - IBCL: indolent B-cell lymphoma
 - IES: industry expert session
 - ISS: independent satellite symposium
 - MCL: mantle cell lymphoma
 - MPN: myeloproliferative neoplasms
 - MTP: Meet-the-Professor
 - TCL: T-cell lymphoma

Note that all times listed are in Central Daylight time CDT (UTC/GMT -5)

